Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations.
In development since 2022, the project has so far seen the completion of safety assessment utilizing intranasal administration at Altasciences’ preclinical site in Columbia, MO. A cardiovascular study was also completed at Altasciences’ preclinical facility in Scranton, PA.
Bioanalytical sample analysis for the GLP studies is currently ongoing. “We are very pleased to be working with Virpax again and are satisfied with the trajectory our studies have taken. The final step for this program will be a bioanalytical sample analysis. Once samples are validated, this will conclude the IND package,” said Kyle Klepner, Senior Scientist, Study Director, Safety Assessment, Altasciences.
Steve Mason, Co-Chief Operating Officer, Altasciences, added: “The creation of AnQlar as a treatment, if successful, could be a huge leap forward in preventing the spread of influenza and similar viruses. We look forward to further collaboration with Virpax in the near-future.”
Dr. Sheila Mathias PhD, Chief Scientific Officer, Virpax, also said of the project: “Our work with Altasciences over the last year has been both exceedingly productive and rewarding demonstrating tangible results, and the nonclinical support provided has been vital in ensuring the progress of this project.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
About Virpax
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™, a single injection liposomal bupivacaine formulation being developed to manage post-operative pain, and Envelta™, an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.
Virpax is also using its intranasal molecular envelope technology (MET) to develop two other product candidates. PES200, is a product candidate being developed to manage PTSD, and NobrXiol™, a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD), for the management of rare pediatric epilepsy.
Having recently acquired global rights to NobrXiol, Virpax has competitive cooperative research and development agreements (CRADAs) for all three of its prescription drug candidates, two with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is currently seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis.
For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230921062012/en/
Contact information
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
Virpax Media:
Robert Cavosi
RooneyPartners
rcavosi@rooneypartners.com
(646) 638-9891
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Booking.com and Antom Partner to Expand Local Payment Options Across Asia15.1.2025 04:47:00 CET | Press Release
Booking.com, one of the world’s leading travel companies, and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership which will enhance the payment experience for Booking.com customers by integrating diverse payment options across key markets in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114445080/en/ This partnership will enable Booking.com to deliver a more tailored customer experience while unlocking business opportunities across China’s Hong Kong SAR, Indonesia, Japan, Malaysia, Singapore, South Korea, Thailand, and the Philippines — markets with a combined population of approximately 680 million. Each market presents distinct challenges, including varying payment methods, currencies and regulatory frameworks. Antom helps global merchants like Booking.com navigate this complexity by leveraging its extensive payment channel partner
Alphemy Capital appoints Barry Schachter as Head of Portfolio Risk Management14.1.2025 21:26:00 CET | Press Release
Alphemy Capital S.A. (“Alphemy Capital”), a leading digital asset and blockchain investment manager, has appointed Barry Schachter as Head of Portfolio Risk Management. Schachter formally joined the firm in January 2025 after nine months as its Risk Management Advisor, where he worked closely with the investment team in developing new tools and analytics to enhance Alphemy Capital’s existing risk management framework. Schachter brings more than 20 years’ experience in executive risk management roles at top hedge funds, including Caxton, SAC, Balyasny, and Moore. An investment industry veteran, he has been instrumental in designing, implementing, and leading risk management functions at multiple firms, for some of these as a member of the pre-launch team. “I am excited to have Barry at Alphemy Capital in this senior leadership role,” said Roman Khrushch, CEO of Alphemy Capital. “Barry’s truly unparalleled combination of experience and expertise strengthens our team in multiple ways.” Ma
Zayed Sustainability Prize Celebrates Innovators Driving Global Progress at 2025 Awards14.1.2025 21:15:00 CET | Press Release
Today, His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, recognised the 2025 winners of the Zayed Sustainability Prize. Celebrating the transformational impact of 11 pioneering organisations and high schools from across the world, the Prize reflects the UAE’s commitment to fostering scalable solutions to global challenges and empowering communities in their pursuit of sustainable prosperity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114367660/en/ Zayed Sustainability Prize celebrates innovators driving global progress at 2025 Awards (Photo: AETOSWire) In a Ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by 11 Heads of State, Ministers, and business leaders, H.H. Sheikh Mohamed bin Zayed awarded the winners for their remarkable achievements, encouraging continued innovation in every corner of the globe. H.H. Sheikh Mohamed bin Zayed said: “The UAE remains steadfast in its co
Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market14.1.2025 18:07:00 CET | Press Release
Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/ Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire) “Justin has bee
Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution14.1.2025 17:45:00 CET | Press Release
Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced general availability of its new DVB ReAccess solutions that serves as a uniquely powerful over-the-air (OTA) Conditional Access System (CAS). The solution also provides users with added peace of mind following the recent completion of Cartesian’s Farncombe Security® Audit. DVB ReAccess addresses a notable hurdle for one-way networks such as broadcast satellite providers that lack bidirectional handshakes to identify and authenticate client devices authorized to decrypt content. In one-way networks, the security of content relies almost exclusively on the resistance and resilience of the CAS, the most secure of which have a client software deeply anchored within the device’s hardware, leveraging a number of security features provided by the chipset. Consequently, once a CAS is integrated on a device, it’s typically very challe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom